Drug intelligence / Profile preview

ATH-301

Development stage: Preclinical
Lead developer: Athos Therapeutics
Modality: Small Molecules

Overview

ATH-301 is a small molecule drug developed by Athos Therapeutics. It is currently in preclinical development and targets diseases in the areas of neoplasms (cancers), immune system diseases, cardiovascular diseases, and fibrosis. The primary indications under investigation include idiopathic pulmonary fibrosis and multiple myeloma. While the precise mechanism of action or molecular target has not been publicly disclosed, Athos Therapeutics focuses on immunomodulatory approaches for autoimmune and fibrotic conditions[1][3][9].

Beyond the preview

Go deeper on ATH-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATH-301.

Explore the full profile